4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4/A - Chromocell Therapeutics Corp (0001919246) (Issuer)

"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation ("Channel" or the "Company"), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. "We are

FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel II, CEO, will present at the upcoming LDMicro and Spartan Capital investor conferences. Details for the conferences and presentations are as follows: LDMicro Main Event XVII (October 28-30, 2024) Presentation: October 29, 2024 Time: 10:00 AM - 10:25 AM PTLocation: Luxe Sunset BLVD Hotel, Los AngelesIn-person registration: LINKVirtual attendance: LINKAvailable for 1x1 meetings: October 29th The Main Event has become the industry stand

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized an amendment (the "Amendment") to the Company's existing stock repurchase plan (as amended, the "Repurchase Plan") to increase the total value of shares of Chromocell's common stock ("Common Stock") available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 20

Chromocell invites individuals, institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. DATE: September 19th TIME: 11:00 AM ETLINK: https://bit.ly/3XjDJkLAvailable for 1x1 meetings: September 19th and September 20th This will be a live, interactive online event where inve

FREEHOLD, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference.  Frank Knuettel, CEO of Chromocell, will provide an overview of the Company's business during the presentation. If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following conference registration link: www.hcwevents.com/annualconference. The virtual presentation will be available after Septembe

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized a stock repurchase plan (the "Repurchase Plan") of up to $250,000 of Chromocell's common stock ("Common Stock"), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will present at the Virtual Investor Lunch Break: The Chromocell Opportunity event on Thursday, July 18, 2024 at 12:00 PM ET. As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Knuettel will answer as many questions as possibl

FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024. The conference provides Alliance Global Partners' top healthcare companies with an opportunity to discuss what they think are important industry catalysts and share some input on where they see the industry progressing in the coming months and years. The showcase will consist of 20-minute ‘fireside chat' style presentations moderated by A.G.P.'

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders: Dear Fellow Stockholders, With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering ("IPO"), share our mission, outline the current status of our development programs, and discuss our growth and operational plans. We successfully closed our IPO on February 21, 2024, raising gross proceeds of approximately $6.6 millio

8-K - Channel Therapeutics Corp (0001919246) (Filer)

8-K12G3 - Channel Therapeutics Corp (0001919246) (Filer)

8-K - Channel Therapeutics Corp (0001919246) (Filer)

424B3 - Chromocell Therapeutics Corp (0001919246) (Filer)

424B3 - Chromocell Therapeutics Corp (0001919246) (Filer)

10-Q - Chromocell Therapeutics Corp (0001919246) (Filer)

8-K - Chromocell Therapeutics Corp (0001919246) (Filer)

DEF 14A - Chromocell Therapeutics Corp (0001919246) (Filer)

PRE 14A - Chromocell Therapeutics Corp (0001919246) (Filer)

424B3 - Chromocell Therapeutics Corp (0001919246) (Filer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

3/A - Chromocell Therapeutics Corp (0001919246) (Issuer)

4/A - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13D - Chromocell Therapeutics Corp (0001919246) (Subject)

Alliance Global Partners analyst James Molloy initiates coverage on Chromocell Therapeutics (AMEX:CHRO) with a Buy rating.

Gainers Innovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million. Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 53.94% to $0.32. The company's market cap stands at $7.5 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 34.56% to $0.27. The company's market cap stands at $4.2 million. Apollomics (NASDAQ:APLM) shares increased by 28.89% to $0.34. The market value of their outstanding shares is at $36.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 25.07% to $0.2. The market value of their outstanding shares is at $4.5 million. Chromocell Therapeuti

Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b

Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session. The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with the second quarter. Super Micro Computer shares dipped 13.2% to $806.00 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Next.e.GO N.V. (NASDAQ:EGOX) shares jumped 129% to $0.0817. Redwoods Acquisition Corp. (NASDAQ:RWOD) shares rose 62.5% to $12.03 after falling around 3% on Thursday. Zhongchao Inc. (NASDAQ:ZCMD) gained 50% to $2.16 after gaining over 7% on Thursday. Ault Alliance, Inc. (NYSE:AULT) surged 46% to $0.3544 after the company

Gainers Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards by 16.62% to $0.57. The market value of their outstanding shares is at $6.2 million. Portage Biotech (NASDAQ:PRTG) shares moved upwards by 14.83% to $0.28. The company's market cap stands at $5.4 million. Erasca (NASDAQ:ERAS) stock rose 13.73% to $2.04. The company's market cap stands at $308.4 million. MSP Recovery (NASDAQ:LIFW) shares moved upwards by 13.25% to $0.94. The company's market cap stands at $14.9 million. As per the press release, Q4 earnings came out 4 days ago. Cue Health

Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ:INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goa

Gainers INVO Bioscience (NASDAQ:INVO) shares increased by 93.4% to $1.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.8 million. As per the press release, Q4 earnings came out yesterday. Clene (NASDAQ:CLNN) shares moved upwards by 40.8% to $0.44. The market value of their outstanding shares is at $56.0 million. Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 31.76% to $0.22. The market value of their outstanding shares is at $12.1 million. Vanda Pharma (NASDAQ:VNDA) stock moved upwards by 26.91% to $5.14. The company's market cap stands at $295.7 million. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 23.62% to $2.25

Shares of INVO Bioscience, Inc. (NASDAQ:INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The company said quarterly revenue surged 397% year-over-year to $1,381,754, from $278,142 in the year-ago period, according to data from Benzinga Pro. INVO Bioscience shares jumped 73.1% to $1.35 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares gained 36.1% to $0.1565 in pre-market trading after falling around 9% on Tuesday. On April 16, Maxim Group analyst Jack Vander Aarde downgraded Mobile Global Esports from Buy to Hold. Chromocell Therapeutics Corporation (NYSE:CHR

Dear Fellow Stockholders,With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering ("IPO"), share our mission, outline the current status of our development programs, and discuss our growth and operational plans.We successfully closed our IPO on February 21, 2024, raising gross proceeds of approximately $6.6 million. Notably, almost all shares of common stock held by 5% holders, directors and officers of the Company prior to the IPO are subject to formal lock-up agreements.Additional key highlights since the close of the IPO include:All pre-IPO outstanding shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") were

Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company's permanent CEO. "I'm grateful to our board of directors and Chromocell's investors for their support over the past seven months and for the confidence they have shown in my ability to lead the Company," said Frank Knuettel, CEO of Chromocell. "I look forward to continuing to work with them and leading the effort to push forward our announced clinical and pre-clinical programs and developing additional programs based on our proprietary non-opioid pain therapy